Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06347016 · ClinicalTrials.gov registry record · Phase 3
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
A Phase 3 study of Severe Hypertriglyceridemia, sponsored by Arrowhead Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 311
- Enrollment target
- 20
- Study locations
NCT06347016: Active Phase 3 study of Severe Hypertriglyceridemia, sponsored by Arrowhead Pharmaceuticals.
NCT06347016 is a Phase 3 study of Severe Hypertriglyceridemia that is active but no longer recruiting, run by Arrowhead Pharmaceuticals. The registered enrollment target is 311 participants, below the 386-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06347016, a Phase 3 study of Severe Hypertriglyceridemia, is active but no longer recruiting, sponsored by Arrowhead Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 311 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After Month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Plozasiran Injection
Study Locations (20)
California
- Research Site 3 - Beverly Hills
- Research Site 4 - Canoga Park
- Research Site 5 - Huntington Beach
- Research Site 6 - Lincoln
- Research Site 7 - Long Beach
- Research Site 8 - Oxnard
Florida
- Research Site 9 - Clearwater
- Research Site 10 - North Miami
- Research Site 11 - Sarasota
Indiana
- Research Site 14 - Elkhart
- Research Site 15 - Indianapolis
- Research Site 16 - South Bend
Alabama
- Research Site 1 - Birmingham
- Research Site 2 - Mobile
Georgia
- Research Site 12 - Lawrenceville
- Research Site 13 - Sugar Hill
Kansas
- Research Site 17 - Overland Park
- Research Site 18 - Topeka
Louisiana
- Research Site 19 - Metairie
Maryland
- Research Site 20 - Annapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 311 participants |
| Start Date | 2024-07-23 |
| Est. Completion | 2026-09 |
| Phase | Phase 3 |
What the registry record for NCT06347016 still lists
NCT06347016 is an interventional study that assigns participants to a tested intervention. The registered 311 participants enrollment target is mid-sized for trials with a published cap, below the 386-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (19% lower).
The record links to 1 condition, with Severe Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06347016 names 20 study sites across 8 states, led by California, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT06347016 about?
NCT06347016 is a clinical study titled "Study of Plozasiran in Adults With Severe Hypertriglyceridemia". This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and...
What is the current status of trial NCT06347016?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 311 participants. The study started on 2024-07-23. Estimated completion is 2026-09.
What conditions does trial NCT06347016 study?
This clinical trial studies the following conditions: Severe Hypertriglyceridemia.
What interventions are being tested in trial NCT06347016?
The interventions under investigation include: Placebo (DRUG), Plozasiran Injection (DRUG).
Who is sponsoring clinical trial NCT06347016?
This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06347016 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06347016's enrollment target sits among peer trials
311 6th of 8 higher than 3 of 8 other Severe Hypertriglyceridemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Severe Hypertriglyceridemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
RECRUITING · Phase 3
-
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
ACTIVE NOT RECRUITING · Phase 3
-
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
COMPLETED · Phase 3
-
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04984551 · 312 participants · Phase 2
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
- NCT04999904 · 312 participants · NA
A Proprioceptive Training Program Using an Uneven Terrain Treadmill for Patients With Ankle Instability
- NCT05220332 · 312 participants · NA
Church-based Intervention to Improve Blood Pressure in African Americans
- NCT05434234 · 312 participants · Phase 1
A Study of YL201 in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI